MAZE Stock — Maze Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$26.53

Market cap

$1.47B

Price action

19 metrics

Price change (1W)

-12.8%

Price change (30D)

-2.9%

Price change (3M)

+9.2%

Price change (6M)

-40.0%

Price change (YTD)

-36.0%

Price change (1Y)

+83.1%

Trailing year

Price change (5Y)

—

52-week high

$51.84

52-week low

$14.97

Change from 52-week high

-48.8%

Change from 52-week low

+77.2%

Annualized volatility

83.4%

Beta

1.1

RSI (14D)

39.9

Price vs SMA 50

-7.4%

Price vs SMA 200

-22.7%

Avg volume (3M)

545,250

Relative volume

0.6

Average dollar volume

$15.16M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

55.55M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

589.5×

reciprocal yield 0.2%

P / book

3.3

reciprocal yield 30.7%

FCF yield

-7.2%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-9.1%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2026-03-25

Profitability

9 metrics

Gross margin

—

Operating margin

34.4%

Trailing 12 months

Net margin

31.2%

Gross profit (TTM)

—

Operating profit (TTM)

−$145.61M

Net income (TTM)

−$133.59M

Trailing 12 months

Diluted EPS (TTM)

$-2.34

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$7.19

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

-351.0%

Revenue (TTM)

$2.50M

Trailing 12 months

EPS growth YoY

-344.0%

Shares change YoY

+34.7%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-29.5%

Return on assets

-25.1%

Debt / equity

0.1

Current ratio

18.3

EBITDA (TTM)

—

Free cash flow (TTM)

−$106.84M

Quick ratio

18.3

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$372.13M

Latest balance sheet

Cash & equivalents

$202.64M

Total assets

$531.62M

Total debt

$38.96M

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$106.54M

Capital expenditures (TTM)

$302,000

R&D (TTM)

$121.85M

SG&A (TTM)

—

Stock compensation (TTM)

$26.23M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

163

13F filer change QoQ

-6

Institutional ownership

105.6%

Short interest

3 metrics

Short interest

10.8%

Latest settlement · 16.2 days to cover

Days to cover

16.2d

Short-squeeze score

73 / 100

Insider activity

2 metrics

Net insider buying (90D)

−$4.19M

Insider-sentiment score

—

Risk flags

1 metrics

Going concern

—

MAZE · Maze Therapeutics, Inc.

MAZE metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search